Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Kaléo Pharma’s EpiPen Alternative Launched with Expensive List Price

XTALKS VITALS NEWS

Auto-Injector

According to a press release issued by Kaléo, the Auvi-Q will be available by prescription starting in mid-February.

Share this!

January 30, 2017 | by Sarah Hand, M.Sc.

Much to the dismay of insurers and pharmacy benefit managers, Kaléo Pharma has announced that the list price for a two-pack of its EpiPen alternative auto-injectors will be set at $4,500. According to a press release issued by Kaléo, the Auvi-Q will be available by prescription starting in mid-February.

“We met with patients and physicians and listened to the very real challenges in the current healthcare environment with obtaining access to affordable medicines,” said Spencer Williamson, President and CEO of Kaléo. “As a result, starting February 14, for more than 200 million Americans with commercial insurance, including those with high-deductible plans, the out-of-pocket cost for Auvi-Q will be $0.”

For uninsured patients whose annual household income is less than $100,000, the Auvi-Q will also be offered free of charge. All other uninsured patients will be subject to a cash price of $360 for the two-pack of Auvi-Q auto-injectors.



According to a report from The Street, major payers like Express Scripts, Cigna and Humana have no plans to cover the cost of the Auvi-Q auto-injector. Instead, the healthcare insurers will continue to pay for other EpiPen alternatives, such as Impax Pharmaceuticals' Adrenaclick, and generic versions of the device.

Healthcare payer, Aetna, told BioPharmaDive that it “will treat the re-entrance of AuviQ as a new drug into the market, as with any other new drug," and "will be placing in a restricted coverage level until a final formulary coverage is determined. With the generic to both EpiPen and the generic to Adrenaclick at Tier 1, as well as brand-name EpiPen at tier 2/Preferred coverage, we have cost-effective alternatives available for our members.”

Auvi-Q auto-injectors were recalled in 2015 after some patients reported issues with inaccurate dosage delivery. Shortly after, Sanofi terminate its licensing deal with Kaléo prompting the company to make some improvements to the device.

“We know how important it is that severely allergic patients have an epinephrine auto-injector that can be with them at all times and used correctly, even without training, during a panic-stricken allergic emergency,” said Dr. Eric Edwards, Vice President of Product Strategy at Kaléo. “We are excited to make Auvi-Q, an epinephrine auto-injector with innovative features, available for millions of patients living with severe, life-threatening allergies.”


Keywords: EpiPen, Drug Pricing, Healthcare Payers


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.